We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Daiichi, ArQule End Phase III Drug Combo Trial
Daiichi, ArQule End Phase III Drug Combo Trial
October 5, 2012
Daiichi Sankyo and ArQule are discontinuing a Phase III trial of tivantinib in combination with erlotinib for patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC).